** Hong Kong-listed shares of Chinese oncology treatments developer Beigene Ltd 6160.HK jump 10.1% to HK$117.40
** Stock marks biggest intraday pct rise since December 2022
** Stock hits the highest point since Dec 10, and on course to snap two sessions of decline, if gains hold; stock is fourth-biggest pct gainer in Hang Seng Composite Index .HSCI, which adds 0.9%
** Beigene says it expects to achieve "positive" operating income for full-year 2025 pursuant to U.S. generally accepted accounting principles
** Beigene's Shanghai stock 688235.SS surges 6.7% to 174.18 yuan, its highest since Dec 10
** Hang Seng Commerce & Industry Index .HSNC rises 1.1%, healthcare index .HSCIH surges 2.4% and Hang Seng Index .HSI gains 0.9%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。